| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_66e061087b8b0ca4bda35df8e395be73 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-145 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-145
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2013-04-19^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ea9c7434c4297d45591d95e54eec0990
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_600dce94aaf50c7831a538767a4253cb |
| publicationDate |
2014-10-29^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20140125644-A |
| titleOfInvention |
Use of cysteamine and derivatives thereof to suppress tumor metastases |
| abstract |
The present disclosure relates to a method of inhibiting or inhibiting tumor metastasis using a cysteamine product, for example, a cysteamine or cystamine or a derivative thereof, in a mammalian subject. Also described herein are methods of treating pancreatic cancer in a mammalian subject by administering a cysteamine product as described herein. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11173135-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20190125832-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11786491-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11612576-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20180120268-A |
| priorityDate |
2013-04-19^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |